The National Comprehensive Cancer Network (NCCN) identifies candidates for pharmacoprevention including women with a 5-year invasive breast cancer risk ≥ 1.7% by the Gail model (with other validated models such as Tyrer-Cuzick informing clinical judgment), those with high-risk histology (ADH, ALH, LCIS), strong family history, or pathogenic variants in susceptibility genes. The gene discussed is AVP; the disease is invasive breast carcinoma.